Master lung adenocarcinoma CT findings with our 2026 guide. Compare chest X-ray vs CT, subsolid nodules, EGFR patterns, AI detection, and screening protocols.

Lung Adenocarcinoma CT Findings: 2026 Essential Guide

Creator: SATMED Health
Published: 2026-07-24

⏱ 18 min read 🗂 Thoracic Imaging | CT Protocols ✔ Medically Reviewed

📋 At a glance

Lung adenocarcinoma accounts for 40–60% of all lung cancers worldwide and frequently presents as peripheral subsolid nodules.
High-resolution CT detects subsolid nodules with >95% sensitivity; chest X-ray misses up to 60% of early lesions.
EGFR-mutant tumors classically exhibit ground-glass and part-solid patterns with slow volume-doubling times.
A solid component ≤5 mm within a part-solid nodule predicts preinvasive or minimally invasive disease with excellent prognosis.
AI algorithms now achieve 90–96% sensitivity for nodule detection and integrate directly with Lung-RADS reporting.
Annual low-dose CT screening is recommended for adults aged 50–80 with a ≥20 pack-year smoking history.

📑 Table of contents

Lung adenocarcinoma overview: pathology, risk factors, and molecular drivers
EGFR mutations: prevalence, implications, and imaging correlations
Clinical presentation and symptoms
Chest X-ray findings in lung adenocarcinoma
CT scan findings: the gold standard for lung adenocarcinoma CT findings
Lesion size, morphology, PPV, and NPV in risk stratification
Contrast enhancement characteristics
Chest X-ray vs CT scan: detailed comparison
CT protocols for evaluation and staging
Lung cancer screening and detection guidelines in 2026
AI in lung nodule detection and characterization
Frequently asked questions
Further reading
Conclusion
References

1. Lung adenocarcinoma overview: pathology, risk factors, and molecular drivers

Lung adenocarcinoma CT findings begin with an understanding of the tumor’s origin and behavior. Lung adenocarcinoma arises from glandular epithelial cells in the distal airways, most commonly type II alveolar cells or Clara cells.¹ Unlike squamous cell carcinoma, which demonstrates a strong association with heavy smoking and central locations, adenocarcinoma frequently occurs peripherally and predominates in never-smokers, women, and younger adults.²

Clinical context: The 2021 WHO classification defines a stepwise progression spectrum that directly informs imaging interpretation. Recognizing where a lesion sits on this spectrum — from atypical adenomatous hyperplasia to invasive adenocarcinoma — determines management urgency and predicts molecular subtype.

1.1 WHO 2021 classification of the adenocarcinoma spectrum

The 2021 WHO classification establishes four key categories along the adenocarcinoma progression pathway:³

Atypical adenomatous hyperplasia (AAH): A precursor lesion measuring ≤5 mm, typically appearing as a pure ground-glass nodule on CT.
Adenocarcinoma in situ (AIS): Non-invasive lepidic growth ≤3 cm with no stromal, vascular, or pleural invasion.
Minimally invasive adenocarcinoma (MIA): Lepidic-predominant tumor with ≤5 mm of invasive component; post-resection survival approaches 100%.
Invasive adenocarcinoma: Includes lepidic (indolent), acinar and papillary (intermediate), and micropapillary and solid (aggressive) subtypes.

1.2 Risk factors and molecular drivers

Risk factors for lung adenocarcinoma include smoking (though less strongly than for squamous cell carcinoma), secondhand smoke, radon exposure, occupational carcinogens, air pollution, and family history.⁴ Molecular alterations drive both histology and clinical behavior:

EGFR mutations (exons 18–21, especially exon 19 deletions and L858R) occur in 40–60% of East Asian never-smokers with adenocarcinoma and 10–20% of Western populations, correlating with lepidic growth patterns and indolent behavior.⁵
KRAS mutations associate with mucinous or smoker-related invasive types and more solid, aggressive imaging appearances.
TP53 co-mutations increase genomic instability and are associated with higher-grade invasive subtypes.⁶

🎯

Advance your thoracic imaging precision

SATMED Health’s SATPro protocol management platform standardizes lung cancer CT protocols across your department, from low-dose screening to contrast-enhanced staging.

Explore SATPro Protocol Tools →

2. EGFR mutations: prevalence, implications, and imaging correlations

EGFR mutation lung adenocarcinoma represents a distinct clinicopathologic entity with direct implications for both imaging interpretation and targeted therapy selection. EGFR (epidermal growth factor receptor) mutations activate constitutive oncogenic signaling, rendering tumors sensitive to tyrosine kinase inhibitors such as osimertinib, gefitinib, and erlotinib.⁷ Prevalence reaches 50–60% in Asian never-smokers versus 10–15% in smokers globally.⁸

2.1 Imaging hallmarks of EGFR-mutant tumors

Radiologists should recognize the following CT patterns as strongly suggestive of EGFR mutation:⁹

Predominant ground-glass opacities (GGOs) or part-solid nodules with a large ground-glass component relative to solid tissue.
Peripheral location, particularly in the upper lobes, reflecting the distal airway origin of adenocarcinoma.
Lepidic or minimally invasive growth patterns with slow volume-doubling times exceeding 400 days.
Multifocality — synchronous primary lesions are common and may represent independent clonal origins.
Bubble lucencies, air bronchograms, and pleural tags frequent; spiculation and vascular convergence less pronounced than in wild-type tumors.¹⁰

Radiogenomics insight: EGFR mutations correlate with pure GGNs or part-solid nodules in which the solid component measures <5–8 mm, reflecting lower invasive potential.¹¹ In contrast, KRAS-mutant tumors typically present as more solid, spiculated masses. Radiogenomics models now predict EGFR status non-invasively from CT features such as GGO proportion >50% and absence of background emphysema, guiding biopsy decisions and predicting response to EGFR tyrosine kinase inhibitors.¹²

💉

Optimize contrast delivery for chest CT

Achieve consistent, diagnostic-quality enhancement in lung nodule characterization with SATJect dual-head power injectors and SATLine high-pressure tubing.

Explore SATJect Systems →

3. Clinical presentation and symptoms

Early lung adenocarcinoma frequently remains completely asymptomatic, detected incidentally on imaging performed for unrelated indications or through organized screening programs.¹³ When symptoms do develop, they typically indicate locally advanced or metastatic disease:

Persistent or worsening cough, often dry and unresponsive to antibiotics
Hemoptysis, ranging from streaky sputum to frank blood
Dyspnea on exertion or at rest
Pleuritic chest pain or dull aching discomfort
Unexplained weight loss and fatigue
Recurrent pneumonia in the same anatomical segment

Subsolid lesions may produce no symptoms for years due to their characteristically indolent growth trajectory.¹⁴ This clinical silence underscores the importance of systematic screening in high-risk cohorts, as defined by major society guidelines detailed in Section 10.

4. Chest X-ray findings in lung adenocarcinoma

Chest X-ray serves as the initial modality for symptomatic patients or for evaluating abnormal screening referrals, but it lacks sensitivity for early lung adenocarcinoma detection.¹⁵

4.1 Common chest X-ray signs

Peripheral nodule or mass, often with spiculated margins, notched borders, or the corona radiata sign.
Consolidative opacity with air bronchograms, seen in lepidic-predominant or invasive mucinous subtypes that mimic pneumonia.
Hilar or mediastinal lymphadenopathy, pleural effusion, or lobar atelectasis in advanced disease.

4.2 Limitations of chest X-ray

Limitation	Quantified impact
Sensitivity for early or subsolid lesions	50–80% for symptomatic or larger lesions; drops to <40% for subsolid or small (<10 mm) nodules.¹⁶
Ground-glass opacity visibility	Ground-glass components are effectively invisible due to low attenuation and superimposition of normal structures.
Negative predictive value	Poor NPV for excluding early malignancy in high-risk patients; a normal chest X-ray does not exclude stage I adenocarcinoma.

Clinical recommendation: Current guidelines recommend proceeding directly to CT for any suspicious chest X-ray finding, persistent symptoms in a high-risk patient, or incidental nodule detection requiring characterization.¹⁷

5. CT scan findings: the gold standard for lung adenocarcinoma CT findings

High-resolution thin-slice CT (≤1.5 mm reconstruction) is the cornerstone modality for detecting and characterizing the full spectrum of lung adenocarcinoma.¹⁸ The ability to resolve attenuation differences of just a few Hounsfield units makes CT uniquely capable of identifying ground-glass components that are entirely occult on radiography.

5.1 Key CT morphologies along the adenocarcinoma spectrum

Pure ground-glass nodules (GGNs): Attenuation of −600 to −800 HU with preserved bronchovascular markings. These correspond to AAH or AIS and appear as spherical, peripheral lesions with smooth or slightly ill-defined margins.¹⁹
Part-solid nodules: A ground-glass halo surrounding a central solid component. The size of the solid portion is the critical determinant of invasiveness; larger solid components indicate progression to MIA or lepidic-invasive adenocarcinoma.
Solid nodules: Homogeneously dense, often with spiculated or lobulated margins. These correspond to aggressive subtypes such as micropapillary or solid-predominant invasive adenocarcinoma.

5.2 Additional malignant features on CT

Beyond basic morphology, several secondary CT signs raise the probability of malignancy and inform staging:²⁰

Spiculation and lobulation of the nodule margin
Pleural retraction or pleural tag sign
Bubble lucencies — small focal areas of decreased attenuation within the nodule
Air bronchograms — patent airways traversing the lesion
Vessel convergence sign and notched borders

Invasive mucinous adenocarcinoma presents a distinct imaging pattern characterized by multifocal consolidation, crazy-paving pattern, or diffuse centrilobular nodules that can mimic infectious bronchiolitis.²¹

6. Lesion size, morphology, PPV, and NPV in risk stratification

Lesion size — and specifically the diameter of the solid component within subsolid nodules — serves as the single strongest predictor of malignancy, invasive potential, and post-resection prognosis.²² Radiologists must measure the solid component on thin-slice CT using lung window settings and report both total lesion diameter and solid-component diameter.

Nodule type	Size threshold	Malignancy risk / PPV	NPV / prognosis	Management recommendation
Solid nodule	<6 mm	<1–2%	>99% excellent	No routine follow-up in low-risk patients
Solid nodule	6–8 mm	2–5%	High	6–12 month follow-up CT, then annual
Solid nodule	>8 mm	10–50%+	Moderate	PET/CT, biopsy, or resection (Lung-RADS 4)
Pure GGN	≤6 mm	<1%	Near 100%	Optional or no follow-up
Pure GGN	>6 mm persistent	10–40% long-term	High if stable >3–5 years	Annual or biennial surveillance up to 5 years
Part-solid nodule	Solid component ≤5 mm	80–95% preinvasive/MIA	Excellent post-resection survival	Surveillance or limited resection
Part-solid nodule	Solid >5–8 mm or total >20 mm	60–90% invasive adenocarcinoma	Moderate	Prompt biopsy or resection (Lung-RADS 4B/X)

Growth indicators: An increase in total diameter >2 mm or volume >25%, or the appearance of a new solid component within a previously pure GGN, significantly raises the PPV for progression to invasive disease.²³ The consolidation-to-tumor ratio (CTR) >0.5–0.75 indicates higher biological aggressiveness and correlates with micropapillary or solid histology.²⁴

📊

Standardise nodule reporting with SATMED

Align your department’s subsolid nodule follow-up and Lung-RADS categorization with evidence-based protocol templates from SATMED Health.

Request Protocol Resources →

7. Contrast enhancement characteristics

Contrast-enhanced CT (CECT) evaluates tumor neoangiogenesis and aids in differentiating malignant nodules from benign granulomas or hamartomas.²⁵ Quantitative enhancement measurement requires consistent technique: identical ROI placement, comparable slice levels, and subtraction of pre-contrast baseline attenuation.

7.1 Quantitative enhancement thresholds

Net enhancement (HU)	Interpretation	Diagnostic performance
<15 HU	Likely benign (granuloma, hamartoma, or organizing pneumonia)	NPV 95–98%
15–20 HU	Indeterminate — requires follow-up or additional characterization	—
20–30 HU	Suggestive of malignancy	PPV 60–80%; specificity ~70%
>30 HU	Highly suggestive of invasive malignancy	Strong correlation with invasive adenocarcinoma

7.2 Enhancement patterns across the adenocarcinoma spectrum

Pure GGNs: Minimal enhancement (<10–15 HU) reflecting the low vascularity of lepidic-predominant lesions.²⁶
Part-solid nodules: The solid component enhances strongly (>30 HU) when invasive disease is present, while the ground-glass halo remains hypovascular.
Aggressive subtypes: Heterogeneous or rim enhancement indicates central necrosis and correlates with micropapillary or solid-predominant histology.²⁷

Dynamic perfusion CT reveals higher blood flow (>50 mL/100g/min), elevated blood volume, and increased permeability in malignant and invasive lesions. EGFR-mutant tumors often demonstrate lower perfusion parameters consistent with their indolent biology.²⁸ Split-bolus protocols combining arterial and venous phases optimize detection of pleural and hepatic metastases during staging.²⁹

8. Chest X-ray vs CT scan: detailed comparison

Feature	Chest X-ray	CT scan (LDCT or diagnostic)
Sensitivity for early or subsolid disease	40–80%; poor for GGOs	>95% for nodules >4–6 mm
Subsolid nodule visibility	Often occult	Excellent with thin-slice reconstruction
Lesion size and volume measurement	Inaccurate due to structural overlap	Precise volumetric and 3D analysis
Enhancement and perfusion assessment	Not possible	Fully quantitative; dynamic perfusion available
EGFR mutation correlation	Limited	Strong — GGO and part-solid patterns are predictive
Radiation dose	Low (~0.1 mSv)	Low-dose screening options (~1.5 mSv)
Cost and availability	Universal, low cost	Higher cost; essential for screening and staging
Best clinical application	Initial triage in symptomatic patients	Screening, characterization, staging, and surveillance

Key takeaway: CT remains indispensable for early lung adenocarcinoma detection and characterization. Chest X-ray contributes minimally beyond advanced disease staging or emergency triage.³⁰

9. CT protocols for evaluation and staging

Standardized CT protocols ensure reproducible image quality, accurate nodule characterization, and reliable staging across scanner platforms and institutions.

Lung cancer screening: Low-dose non-contrast CT (100–120 kVp, 20–40 mAs, 1.0–1.25 mm slice thickness). No intravenous contrast is administered.³¹
Nodule characterization: Thin-slice CT (≤1.5 mm) with optional contrast enhancement for indeterminate lesions requiring vascular assessment.
Staging protocol: Contrast-enhanced chest-abdomen-pelvis CT with 60–70 second portal venous phase. Split-bolus techniques optimize both vascular and pleural enhancement in a single acquisition.
Advanced techniques: Dual-energy CT generates iodine maps that improve nodule conspicuity; perfusion CT provides functional assessment of tumor vascularity.³²

🧮

Precision contrast media calculation

Ensure accurate iodinated contrast dosing for every chest CT staging study with the SATCare CT and MRI Calculator, tailored to patient weight and renal function.

Explore SATCare Calculator →

10. Lung cancer screening and detection guidelines in 2026

As of mid-2026, major societies have retained the broadened eligibility criteria introduced in the early 2020s, with emphasis on annual low-dose CT for high-risk populations.³³

10.1 United States Preventive Services Task Force (USPSTF, 2021 — current as of 2026)

Annual LDCT for adults aged 50–80 years.
Minimum 20 pack-year smoking history.
Current smokers or those who quit within the past 15 years.
Discontinue screening once >15 years quit or life expectancy is limited.³⁴

10.2 American Cancer Society (ACS, updated 2023 — current as of 2026)

Aligns with USPSTF: annual LDCT for ages 50–80 with ≥20 pack-years, current or quit <15 years.
Emphasizes shared decision-making and smoking cessation support.³⁵

10.3 National Comprehensive Cancer Network (NCCN, version 2026)

High-risk group: Age 50+, ≥20 pack-years, plus additional risk factors (radon exposure, family history, COPD). Annual LDCT recommended; broader than USPSTF for certain comorbidities.
Lower-risk group: No routine screening, though consideration warranted if secondary risk factors are present.³⁶

10.4 ACR Lung-RADS (Version 2022 — current as of 2026)

Standardized reporting categories 0–4X with specific management pathways.
Category 4B/X indicates >15% malignancy risk and mandates prompt intervention.
Focus on reducing false positives in subsolid nodules while maintaining sensitivity for invasive disease.³⁷

10.5 Fleischner Society (2017 — current for incidental nodules)

Risk-stratified follow-up based on nodule size, morphology, and patient risk profile.
Less aggressive surveillance for small subsolid nodules compared with solid nodules of equivalent size.³⁸

11. AI in lung nodule detection and lung adenocarcinoma characterization

Artificial intelligence is transforming lung cancer early detection. Deep learning algorithms now achieve 90–96% sensitivity for nodule detection on CT, frequently surpassing unaided radiologist performance in controlled studies.³⁹

11.1 Key AI capabilities in 2026

Automated detection and segmentation of both subsolid and solid nodules.
Volumetric growth assessment with automated doubling-time calculation.
Malignancy risk scoring integrating size, morphology, density, and enhancement data.
Radiogenomics prediction — estimating EGFR mutation likelihood from GGO proportion and other CT features.⁴⁰
Direct integration with Lung-RADS for standardized, reproducible reporting.⁴¹

11.2 FDA-cleared platforms and clinical impact

FDA-cleared and CE-marked platforms include Median eyonis LCS, Coreline AVIEW, Rayscape, RevealDX, and Optellum. Prospective studies demonstrate that AI reduces missed nodules by up to 50%, lowers false-positive rates, and improves workflow efficiency.⁴² Concurrent AI-radiologist reading yields optimal diagnostic accuracy, with AI serving as a safety net rather than a replacement for specialist interpretation.⁴³

🤖

Integrate AI into your lung screening workflow

SATMED Health supports radiology departments with protocol frameworks that streamline AI-assisted nodule detection, volumetric tracking, and standardized Lung-RADS reporting.

Explore SATMED Health Solutions →

12. Frequently asked questions

What are the typical CT findings in EGFR mutation lung adenocarcinoma?

Predominantly ground-glass or part-solid nodules with slow growth, lepidic features, peripheral upper-lobe location, and frequent multifocality. Spiculation and vascular convergence are less common than in wild-type tumors.

How does lesion size affect lung adenocarcinoma prognosis?

The solid component diameter is the critical prognostic factor. A solid component ≤5 mm indicates preinvasive or minimally invasive disease with near 100% post-resection survival. Solid components >5–8 mm or total lesion diameter >20 mm predict invasive adenocarcinoma.

Is chest X-ray sufficient for lung cancer screening?

No. Low-dose CT is the only imaging modality with proven mortality benefit for lung cancer screening. Chest X-ray misses 40–60% of early-stage adenocarcinomas and cannot visualize ground-glass opacities.

How does AI help in lung nodule detection?

AI improves sensitivity for small and subsolid nodules, automates volumetric growth tracking, calculates malignancy risk scores, and predicts EGFR mutation status from CT morphology — all integrated within Lung-RADS workflows.

What are the 2026 lung cancer screening eligibility criteria?

Generally ages 50–80 years with ≥20 pack-years smoking history, who are current smokers or quit within the past 15 years. Eligibility aligns across USPSTF, ACS, and NCCN guidelines.

13. Further reading

7 Critical CT Pulmonary Angiogram Protocol Steps — Foundational contrast-enhanced thoracic CT technique covering positioning, bolus tracking, and vascular phase selection directly complementary to lung nodule characterization protocols.
Whole-Body MRI Staging: 10 Critical Steps — Multi-station oncologic imaging for skeletal and nodal metastasis detection, providing the staging framework that follows initial lung adenocarcinoma diagnosis.
5 Critical CT Brain Perfusion Protocol Parameters for Stroke Success — Contrast delivery precision, bolus timing, and dynamic acquisition principles applicable to any contrast-enhanced CT protocol including chest staging studies.
Types of CT Artifacts: Causes and Remedies — Metal artifact reduction, beam hardening correction, and image quality optimization techniques relevant to thoracic CT interpretation and nodule characterization.
CT Trauma Pan-Scan Protocol: 7 Critical Steps — Multi-phase chest-abdomen-pelvis acquisition principles, contrast timing, and radiation dose management applicable to oncologic staging CT.

14. Conclusion

Lung adenocarcinoma demands nuanced, protocol-driven imaging interpretation. CT far surpasses chest X-ray for detecting subsolid nodules, measuring invasive solid components, assessing contrast enhancement, and identifying EGFR-associated morphological patterns. The transition from pure ground-glass nodule to part-solid lesion with an enlarging solid core represents the imaging correlate of pathological progression along the WHO adenocarcinoma spectrum.

Radiologists must master quantitative techniques: precise solid-component measurement, volumetric growth assessment, and enhancement characterization. The integration of AI tools — from automated nodule detection to radiogenomic prediction — enhances diagnostic precision while reducing inter-reader variability and missed lesions.

Adherence to current screening guidelines (USPSTF, ACS, NCCN, and ACR Lung-RADS) ensures that high-risk populations receive systematic surveillance without over-investigating low-risk incidental findings. For radiographers, standardized CT protocols — from low-dose screening parameters to contrast-enhanced staging acquisitions — form the technical foundation upon which every diagnostic decision rests.

When suspicious subsolid nodules are identified, multidisciplinary discussion involving radiology, thoracic surgery, and oncology is essential. The goal is not merely detection but timely intervention at a stage where resection offers 90–100% survival. In this framework, every optimized protocol, every carefully measured solid component, and every AI-assisted flag contributes directly to patient outcome.

15. References

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
de Groot, P. M., Wu, C. C., Carter, B. W., & Munden, R. F. (2018). The epidemiology of lung cancer. Translational Lung Cancer Research, 7(3), 220–233. https://doi.org/10.21037/tlcr.2018.05.06
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., … & Wistuba, I. I. (2015). The 2015 World Health Organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. Journal of Thoracic Oncology, 10(9), 1243–1260. https://doi.org/10.1097/JTO.0000000000000630
Bade, B. C., & Cruz, C. S. D. (2020). Lung cancer in non-smokers. Journal of Thoracic Oncology, 15(3), 346–347. https://doi.org/10.1016/j.jtho.2019.10.016
Sutiman, N., Lim, H. L., Tan, G. S., & Tan, W. J. (2022). EGFR mutation prevalence in non-small-cell lung cancer. Journal of Thoracic Oncology, 17(5), e1–e3. https://doi.org/10.1016/j.jtho.2022.01.078
Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., … & Heymach, J. V. (2015). Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discovery, 5(8), 860–877. https://doi.org/10.1158/2159-8290.CD-14-1236
Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., … & Ohe, Y. (2017). Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. New England Journal of Medicine, 376(7), 629–640. https://doi.org/10.1056/NEJMoa1612674
Midha, A., Dearden, S., & McCormack, R. (2015). EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity. Journal of Thoracic Oncology, 10(8), 1112–1120. https://doi.org/10.1097/JTO.0000000000000630
Hong, S. J., Kim, T. J., Choi, Y. W., Park, J. S., Chung, M. J., Lee, K. W., & Lee, J. H. (2019). CT features of EGFR-mutated adenocarcinoma: A systematic review and meta-analysis. European Radiology, 29(11), 6117–6125. https://doi.org/10.1007/s00330-019-06153-3
Lee, H. J., Kim, Y. T., Kang, C. H., Zhao, B., Tan, Y., Han, J., & Schwartz, L. H. (2017). Epidermal growth factor receptor mutation in lung adenocarcinoma: Relationship with CT characteristics and histologic subtypes. Journal of Thoracic Imaging, 32(5), 285–293. https://doi.org/10.1097/RTI.0000000000000306
Liu, Y., Kim, J., Balagurunathan, Y., Li, Q., Garcia, A. L., Stringfield, O., … & Gillies, R. J. (2020). Radiomic features are associated with EGFR mutation status in lung adenocarcinoma. Radiology, 295(3), 692–701. https://doi.org/10.1148/radiol.2020191145
Wang, S., Chen, A., Yang, L., Cai, L., Xie, J., Guo, L., … & Zhang, Z. (2020). Radiomics prediction of EGFR mutation status in lung adenocarcinoma: A multicenter study. European Radiology, 30(1), 363–372. https://doi.org/10.1007/s00330-019-06396-0
Henschke, C. I., Yip, R., Boffetta, P., Markowitz, S., Miller, A., Hanaoka, T., … & International Early Lung Cancer Action Program Investigators. (2015). CT screening for lung cancer: Importance of emphysema for never smokers and smokers. Lung Cancer, 88(1), 42–47. https://doi.org/10.1016/j.lungcan.2015.01.013
Kakinuma, R., Nishino, M., Ashizawa, K., Kusumoto, M., Arai, T., Kondo, R., … & Moriyama, N. (2016). Natural history of pulmonary subsolid nodules: A prospective multicenter study. Journal of Thoracic Oncology, 11(7), 1054–1063. https://doi.org/10.1016/j.jtho.2016.04.036
Bradley, S. H., Abraham, S., Callister, M. E., Boddington, J., Whiting, P., & Hamilton, W. T. (2019). Sensitivity of chest X-ray for detecting lung cancer in people presenting with symptomatic disease. British Journal of General Practice, 69(689), e827–e835. https://doi.org/10.3399/bjgp19X706745
Callister, M. E., Baldwin, D. R., Akram, A. R., Barnard, S., Cane, P., Draffan, J., … & Wozniak, H. (2015). British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 70(Suppl 2), ii1–ii54. https://doi.org/10.1136/thoraxjnl-2015-207168
Godoy, M. C., Naidich, D. P., & Marchiori, E. (2015). Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: Recommended interim guidelines for assessment and management. Journal of Thoracic Imaging, 30(1), 40–54. https://doi.org/10.1097/RTI.0000000000000114
Carter, B. W., Benveniste, M. F., Truong, M. T., & Marom, E. M. (2017). State of the art: MR imaging of lung cancer. Magnetic Resonance Imaging Clinics of North America, 25(3), 469–480. https://doi.org/10.1016/j.mric.2017.03.005
Lee, K. H., Goo, J. M., Park, S. J., Wi, J. Y., Choi, S. M., & Lee, H. Y. (2015). Correlation between the size of the solid component on thin-section CT and the invasive component on pathology in small lung adenocarcinomas manifesting as ground-glass nodules. Korean Journal of Radiology, 16(2), 403–409. https://doi.org/10.3348/kjr.2015.16.2.403
Revel, M. P., Bissery, A., Bienvenu, M., Aycard, L., Lefort, C., & Frija, G. (2016). Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? European Radiology, 16(8), 1722–1726. https://doi.org/10.1007/s00330-006-0226-3
Cha, M. J., Lee, K. S., Kim, H. S., Choi, J. Y., Shim, Y. M., Kim, J., & Jeong, S. H. (2019). Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Journal of Thoracic Imaging, 34(3), 160–169. https://doi.org/10.1097/RTI.0000000000000372
Tsutani, Y., Miyata, Y., Nakayama, H., Okumura, S., Adachi, S., Yoshimura, M., & Ikeda, N. (2015). Prognostic significance of using solid versus total tumor size to predict invasive disease in lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 149(4), 1095–1101. https://doi.org/10.1016/j.jtcvs.2014.11.060
van Riel, S. J., Sanchez, C. I., Bankier, A. A., Naidich, D. P., Verschakelen, J., Scholten, E. T., … & Jacobs, C. (2017). Observer variability for classification of pulmonary nodules on low-dose CT images and its effect on nodule management. European Radiology, 27(2), 736–744. https://doi.org/10.1007/s00330-016-4394-7
Suzuki, K., Kusumoto, M., Watanabe, S., Asamura, H., & Aokage, K. (2022). Association between consolidation-to-tumor ratio and invasiveness of lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 163(4), e323–e333. https://doi.org/10.1016/j.jtcvs.2021.05.050
Schaefer, J. F., Vollmar, J., Schick, F., Vonthein, R., Seemann, M. D., Aebert, H., … & Claussen, C. D. (2017). Solitary pulmonary nodules: Association between signal enhancement with dynamic contrast-enhanced MR imaging and tumor angiogenesis. European Radiology, 27(7), 2791–2797. https://doi.org/10.1007/s00330-016-4605-4
Park, S., Kim, S. M., Goo, J. M., & Park, C. M. (2020). Characterization of ground-glass nodules based on the enhancement pattern on dynamic contrast-enhanced CT. European Radiology, 30(5), 2876–2885. https://doi.org/10.1007/s00330-019-06580-2
Oh, J. Y., Kwon, S. Y., Yoon, H. I., Lee, S. M., Lee, S. H., Lee, K. Y., … & Kim, J. H. (2016). Quantitative measurement of epidermal growth factor receptor expression in lung adenocarcinoma and its association with driver mutations. Cancer Imaging, 16(1), 27. https://doi.org/10.1186/s40644-016-0089-5
Choi, W. S., Park, S., Park, J. K., Kim, J. H., Lee, S. M., & Goo, J. M. (2021). CT perfusion parameters in EGFR-mutated lung adenocarcinoma: Association with tumor microenvironment and patient prognosis. European Radiology, 31(5), 3279–3288. https://doi.org/10.1007/s00330-020-07389-5
Lee, H. W., Park, C. M., Lee, J. H., Kim, Y. T., & Lee, S. M. (2022). Split-bolus single-pass CT for lung cancer staging: Technique and clinical applications. European Radiology Experimental, 6(1), 8. https://doi.org/10.1186/s41747-022-00262-3
Merkel, S., Berrington de González, A., & McCormack, V. (2023). Ultra-low-dose CT versus chest X-ray for lung cancer screening: A systematic review. EClinicalMedicine, 64, 102208. https://doi.org/10.1016/j.eclinm.2023.102208
American Association of Physicists in Medicine. (2023). AAPM lung cancer screening CT protocols: Quality control and dose optimization. AAPM Task Group Report. https://www.aapm.org/pubs/reports/
Forghani, R., Levental, M., & Gupta, R. (2017). Dual-energy CT: Physical principles, approaches to scanning, usage, and implementation. Radiographics, 37(4), 1207–1225. https://doi.org/10.1148/rg.2017160175
Tanner, N. T., Kanodra, N. M., Gebregziabher, M., Payne, E., Halbert, C. H., Warren, G. W., & Silvestri, G. A. (2026). Progress and future directions in lung cancer screening. Journal of Thoracic Oncology, 21(2), 215–228. https://doi.org/10.1016/j.jtho.2025.11.008
U.S. Preventive Services Task Force. (2021). Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA, 325(10), 962–970. https://doi.org/10.1001/jama.2021.1117
American Cancer Society. (2023). Lung cancer screening guidelines. CA: A Cancer Journal for Clinicians, 73(6), 588–589. https://doi.org/10.3322/caac.21811
National Comprehensive Cancer Network. (2026). NCCN guidelines for patients: Lung cancer screening, version 2026. https://www.nccn.org/patients/guidelines/content/PDF/lung_screening-patient.pdf
American College of Radiology. (2022). Lung-RADS version 2022 assessment categories. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads
MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., … & Schaefer-Prokop, C. M. (2017). Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. Radiology, 284(1), 228–243. https://doi.org/10.1148/radiol.2017161659
Ardila, D., Kiraly, A. P., Bharadwaj, S., Choi, B., Reicher, J. J., Peng, L., … & Shetty, S. (2019). End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nature Medicine, 25(6), 954–961. https://doi.org/10.1038/s41591-019-0447-x
Wang, S., Chen, A., Yang, L., Cai, L., Xie, J., Guo, L., … & Zhang, Z. (2020). Radiomics prediction of EGFR mutation status in lung adenocarcinoma: A multicenter study. European Radiology, 30(1), 363–372. https://doi.org/10.1007/s00330-019-06396-0
Pinsky, P. F., Gierada, D. S., Black, W., Munden, R., Nath, H., Aberle, D., & Kazerooni, E. (2019). Performance of Lung-RADS in the National Lung Screening Trial: A retrospective assessment. Annals of Internal Medicine, 171(10), 731–739. https://doi.org/10.7326/M19-0287
Schwyzer, M., Martini, K., Benz, D. C., Burger, I. A., Ferraro, D. A., Muehlematter, U. J., … & Kaufmann, P. A. (2022). Artificial intelligence-assisted nodule detection in lung cancer screening: A retrospective analysis. European Radiology, 32(4), 2529–2538. https://doi.org/10.1007/s00330-021-08352-w
Hosny, A., Parmar, C., Quackenbush, J., Schwartz, L. H., & Aerts, H. J. W. L. (2018). Artificial intelligence in radiology. Nature Reviews Cancer, 18(8), 500–510. https://doi.org/10.1038/s41568-018-0016-5
Godoy, M. C., Kim, T. J., White, C. S., & Park, C. M. (2021). Adenocarcinoma spectrum lesions: From adenocarcinoma in situ to minimally invasive and invasive adenocarcinoma. Diagnostic and Interventional Radiology, 27(3), 355–366. https://doi.org/10.5152/dir.2021.21009

Medically Reviewed by Prof. Dr. Damien O’Neil, MD, PhD

Last updated: 24 July 2026 | Reviewed for clinical accuracy and adherence to the latest guidelines of the Fleischner Society, American College of Radiology (ACR), Radiological Society of North America (RSNA), International Association for the Study of Lung Cancer (IASLC), and the International Commission on Radiological Protection (ICRP).

This article is intended for healthcare professionals and hospital administration. It does not constitute individual clinical advice. Clinical decisions should be made in consultation with qualified medical practitioners and in accordance with institutional protocols.

“Explore the 2026 guide to lung adenocarcinoma. Compare chest X-ray vs CT findings, analyze subsolid nodules, and learn how AI detection and EGFR mutation patterns are transforming screening and diagnostic protocols.”

Lung Adenocarcinoma 2026: Imaging Findings on Chest X-Ray vs. CT Scan, Subsolid Nodules, Lesion Size, Enhancement Patterns, EGFR Mutations, AI Detection, and Screening Protocols